Elvia Cowan Sells 5,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,017,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vaxcyte Trading Up 1.2 %

PCVX stock opened at $81.96 on Friday. The stock’s fifty day simple moving average is $72.65 and its two-hundred day simple moving average is $69.03. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $83.36. The stock has a market cap of $8.92 billion, a P/E ratio of -19.15 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.28. As a group, analysts forecast that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

PCVX has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Friday, June 28th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after buying an additional 312,500 shares during the period. Janus Henderson Group PLC raised its stake in shares of Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after buying an additional 692,492 shares during the period. Wellington Management Group LLP raised its stake in shares of Vaxcyte by 3.8% in the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after buying an additional 167,501 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of Vaxcyte by 20.4% in the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after buying an additional 700,414 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.